083790.Kq

The company's capital structure is characterized by a debt-to-equity ratio of 0.78, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 0.51, suggesting limited short-term liquidity to cover immediate obligations. The price-to-book ratio of 0.83 implies that the company's market value is trading below its book value, which may reflect investor concerns about its financial health or future earnings potential.

Profitability metrics show significant underperformance relative to industry norms. The company reported a net loss of KRW 3.52 billion, with a return on equity of -3.35% and a return on assets of -1.57%. These figures indicate that the company is not generating returns that meet the cost of capital, which is a critical concern for stakeholders. The negative operating income of KRW 23.75 billion further underscores the company's operational challenges.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, particularly in the pharmaceuticals industry, where regulatory and competitive pressures can significantly impact revenue streams. The absence of segment or geographic breakdown in the financial data limits the ability to assess the company's exposure to different markets.

The company's growth trajectory is currently negative, with a net loss and declining operating cash flow. The outlook for the current fiscal year suggests continued financial pressure, with no clear indication of a turnaround in the near term. The company's capital expenditures of KRW 7.99 billion were funded through operational cash flow, which was negative at KRW 17.41 billion, indicating a reliance on external financing or asset sales to maintain operations.

Risk factors include a high level of debt, with long-term debt of KRW 82.52 billion, and a negative net cash position after subtracting total debt. The risk of dilution is assessed as low, but the company's financial performance raises concerns about its ability to meet debt obligations without issuing additional shares. The risk assessment also highlights the need for close monitoring of liquidity and debt management strategies.

Recent events, as reflected in the latest financial filing, show a continuation of financial losses and negative cash flows. The company has not disclosed any material events or strategic initiatives that could signal a potential recovery. The absence of positive developments in the recent financial data suggests that the company may need to implement significant cost-cutting measures or seek alternative financing to stabilize its financial position.